Pharming (PHAR) Operating Leases (2019 - 2025)

Pharming's Operating Leases history runs 7 years deep, the most recent figure standing at $14.4 million for Q4 2025.

• Quarterly Operating Leases fell 52.03% year-over-year to $14.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.4 million (down 52.03% YoY) and the FY2025 annual result came in at $14.4 million, down 52.03% from the prior year.
• Operating Leases was $14.4 million for Q4 2025 at Pharming, down from $29.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $33.3 million in Q4 2022 and bottomed at $14.4 million in Q4 2025.
• A 5-year average of $26.3 million and a median of $29.9 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases jumped 110.94% — and 2025, when it plunged 52.03%.
• Pharming's Operating Leases stood at $20.9 million in 2021, then soared by 59.56% to $33.3 million in 2022, then declined by 0.56% to $33.1 million in 2023, then dropped by 9.69% to $29.9 million in 2024, then plunged by 52.03% to $14.4 million in 2025.
• Business Quant data shows PHAR's Operating Leases at $14.4 million in Q4 2025, $29.9 million in Q4 2024, and $33.1 million in Q4 2023.